

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims**

1. (Previously presented) An isolated tolerogenic dendritic cell comprising an oligodeoxyribonucleotide having one or more NF- $\kappa$ B binding sites, wherein the oligodeoxyribonucleotide inhibits NF- $\kappa$ B transcriptional activity, and wherein the oligodeoxyribonucleotide has the sequence set forth in SEQ ID NO:1.
2. (Previously presented) The isolated tolerogenic dendritic cell of claim 1 wherein the oligodeoxyribonucleotide sequence has two NF- $\kappa$ B binding sites.
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Previously presented) A method of producing an isolated tolerogenic dendritic cell comprising (a) propagating an immature isolated dendritic cell from a mammalian donor, (b) incubating the immature isolated dendritic cell with an oligodeoxyribonucleotide having at least one NF- $\kappa$ B binding site under conditions wherein the immature isolated dendritic cell internalizes the oligodeoxyribonucleotide, wherein the oligodeoxyribonucleotide inhibits NF- $\kappa$ B transcriptional activity and (c) culturing the isolated dendritic cell of (b) to produce the isolated tolerogenic dendritic cell, and wherein the oligodeoxyribonucleotide has the sequence set forth in

NY02:511370.1

SEQ ID NO:1.

8. (Cancelled)

9. (Previously presented) The method of claim 7 further comprising incubating the isolated tolerogenic dendritic cell in the presence of one or more cytokine(s).

10. (Original) The method of claim 9 wherein the cytokine is GM-CSF.

11. (Previously presented) The method of claim 9 further comprising incubating the isolated tolerogenic dendritic cell in the presence of TGF- $\beta$ .

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Previously presented) A kit for enhancing tolerogenicity in a mammalian host comprising tolerogenic dendritic cells which comprise an oligodeoxyribonucleotide having at least one NF- $\kappa$ B binding site, wherein the oligodeoxyribonucleotide inhibits NF- $\kappa$ B transcriptional activity, and wherein the oligodeoxyribonucleotide has a sequence set forth in SEQ ID NO:1.

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35-67. (Cancelled)